Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

NCT05144009 ·Status: TERMINATED ·Phase: PHASE2

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

NCT06788964 ·Status: RECRUITING ·Phase: PHASE2

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

NCT03684694 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

NCT04300803 ·Status: APPROVED_FOR_MARKETING

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

NCT05270057 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669 ·Status: RECRUITING ·Phase: PHASE2

Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

NCT06918912 ·Status: RECRUITING ·Phase: PHASE2

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

NCT05464719 ·Status: RECRUITING ·Phase: PHASE2

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

NCT06919939 ·Status: RECRUITING ·Phase: PHASE2

Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

NCT05222438 ·Status: WITHDRAWN ·Phase: PHASE2

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

NCT05453396 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

NCT04974996 ·Status: WITHDRAWN ·Phase: PHASE1

Long-term Registry of Patients Treated With Loncastuximab Tesirine

NCT05160064 ·Status: WITHDRAWN

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

NCT05660395 ·Status: RECRUITING ·Phase: PHASE1

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

NCT05249959 ·Status: RECRUITING ·Phase: PHASE2

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236 ·Status: RECRUITING ·Phase: PHASE2

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

NCT04855253 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711 ·Status: RECRUITING ·Phase: PHASE1

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

NCT05228249 ·Status: WITHDRAWN ·Phase: PHASE1

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

NCT04974216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

NCT00712582 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

NCT01092182 ·Status: COMPLETED ·Phase: PHASE2

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT00978432 ·Status: TERMINATED ·Phase: PHASE2

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

NCT04699461 ·Status: TERMINATED ·Phase: PHASE2